Back to results
US 11,077,140 B2Granted
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
AssigneeMemorial Sloan Kettering Cancer Center
InventorsMichel Sadelain, Matthias Stephan
Life of this patent
Estimating the term…
Abstract
The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen-recognizing receptor and a co-stimulatory ligand and methods of use therefore for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
Claims15
A method of treating leukemia or ovarian cancer in a subject, comprising administering an effective amount of immunoresponsive cells to the subject, wherein the immunoresponsive cell comprises:
- a) a chimeric antigen receptor (CAR) that binds to a tumor antigen expressed by leukemia or ovarian cancer, and b) a nucleic acid molecule encoding a recombinant IL-12.
Dependencies are inferred from the claim text.